Study of Safety and of the Mechanism of BLZ945 in ALS Patients
Conditions
Diseases of the Nervous System
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.
- Ages18 years - 75 years
- GenderBoth
- Trial withNovartis Pharmaceuticals
- Start Date02/28/2022
- End Date04/05/2022
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Last Updated03/09/2022
- Study HIC#2000026495